Detailed Narrative
Q1 FY27 Performance Amidst Headwinds
Epigral Limited reported a resilient Q1 FY27, achieving 15% revenue growth to INR709 crores and a 25% increase in adjusted PAT to INR99 crores. This performance was delivered despite a highly challenging operating environment marked by the West Asia conflict, severe shipping disruptions, and market volatility🌐. However, the EBITDA margin compressed to 25% from 27% in Q1 FY26, and ROCE declined to 16% (18% excluding capital work in progress) from 24% YoY, primarily due to lower trailing earnings and significant capital work in progress.
Strategic Capex for Diversification and Integration
The company announced a strategic capex plan of INR600 crores for two new projects: a 125,000 tons per annum Epoxy Resin & Formulations plant and a Multipurpose Plant. This expansion is strategically significant as over 50% of the raw material value, including epichlorohydrin and caustic soda, will be sourced internally, strengthening integration advantages. The Multipurpose Plant will target downstream products of epichlorohydrin and chlorotoluenes for pharmaceutical, agrochemical, and water treatment chemicals.
New Project Timelines and Market Outlook
A pilot facility for both the epoxy resin/formulations and the Multipurpose Plant is expected to be operational by Q2 FY27, which will aid in product validation and early customer approvals. Management projects the new epoxy and MPP projects to generate peak revenues between INR1,000-1,500 crores, with chlorotoluenes (existing and new MPP) contributing INR700-800 crores to the top line. The company aims for a 15-20% CAGR over the next five years, driven by India's growing demand in end-user industries like infrastructure, automotive, and renewable energy.
Raw Material and Product Realization Dynamics
The quarter saw ECU realizations in the range of INR35,000-36,000, with current levels at INR31,000-32,000, while chlorine realizations were negative at approximately INR4,000. ECH realizations fluctuated, currently around INR180-185, down from earlier highs of INR200-210 but recovering from a low of INR175. Management clarified that the Minimum Import Price (MIP) primarily impacts carbide-based PVC, not their ethylene-based CPVC, thus mitigating direct negative impact on their CPVC pricing.
Capacity Utilization and Future Growth
Capacity utilization varied across segments, with chloromethanes at 100%, peroxide at 85-90%, caustic soda at 75%, ECH at 70-75%, and CPVC at 50-55%. Management acknowledged short-term overcapacity and demand weakness in CPVC but expressed confidence in long-term absorption due to India's infrastructure growth. They also confirmed that additional Epichlorohydrin and CPVC capacities are expected to be commissioned in the next couple of months, further supporting future growth.
Capital Structure and Funding
The company reported a net debt of INR474 crores and a net debt-to-EBITDA ratio of 0.8x as of June 30, 2026. The INR600 crore strategic capex for new projects will be funded with a mix of 40% internal accruals and 60% debt. The company also confirmed a tax rate of approximately 25% for the coming periods.